These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 3375962)

  • 1. Resolution of malignant ascites after intraperitoneal chemotherapy in women with carcinoma of the ovary.
    Lind SE; Cashavelly B; Fuller AF
    Surg Gynecol Obstet; 1988 Jun; 166(6):519-22. PubMed ID: 3375962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites.
    Garofalo A; Valle M; Garcia J; Sugarbaker PH
    Eur J Surg Oncol; 2006 Aug; 32(6):682-5. PubMed ID: 16631341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and future options in the treatment of malignant ascites in ovarian cancer.
    Woopen H; Sehouli J
    Anticancer Res; 2009 Aug; 29(8):3353-9. PubMed ID: 19661355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of advanced ovarian juvenile granulosa cell tumors.
    Schneider DT; Calaminus G; Wessalowski R; Pathmanathan R; Harms D; Göbel U
    Klin Padiatr; 2002; 214(4):173-8. PubMed ID: 12165898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Laparoscopic intraperitoneal hyperthermic perfusion in palliation of malignant ascites. Case report].
    Graziosi L; Bugiantella W; Cavazzoni E; Donini A
    G Chir; 2009 May; 30(5):237-9. PubMed ID: 19505418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer.
    Recio FO; Piver MS; Hempling RE; Driscoll DL
    Gynecol Oncol; 1998 Mar; 68(3):267-73. PubMed ID: 9570979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A patient with stage IIIc ovarian cancer with massive ascites who was chemotherapy resistant showed complete response with intraperitoneal hyperthermic chemoperfusion].
    Kobayashi K; Fujimoto S; Takahashi M; Mutou T; Toyosawa T; Ohtsuka Y; Ogasawara T
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1726-8. PubMed ID: 14619504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [An aged patient with stage IV ovarian cancer successfully treated by intraperitoneal consecutive administration of cisplatin].
    Narimatsu A; Okada O
    Gan To Kagaku Ryoho; 1998 Jul; 25(8):1225-9. PubMed ID: 9679588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FP therapy for controlling malignant ascites in advanced pancreatic cancer patients.
    Yonemori K; Okusaka T; Ueno H; Morizane C; Takesako Y; Ikeda M
    Hepatogastroenterology; 2007 Dec; 54(80):2383-6. PubMed ID: 18265670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intraperitoneal (i.p.) chemotherapy in the management of ovarian cancer--pharmacokinetics and methods of sequential i.p. chemotherapy].
    Noda T; Adachi S; Yamamoto T; Hirooka C; Kiyozuka Y; Adachi S; Oku M; Ichijo M
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 2):1561-8. PubMed ID: 2389949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route.
    Casper ES; Kelsen DP; Alcock NW; Lewis JL
    Cancer Treat Rep; 1983 Mar; 67(3):235-8. PubMed ID: 6682012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
    Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
    Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
    Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
    Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abdominal stop flow infusion breaks drug resistance in systemically pretreated progressive FIGO IIIc and IV ovarian cancer.
    Aigner KR; Gailhofer S; Brammer C
    Gan To Kagaku Ryoho; 1998 Jan; 25(1):111-4. PubMed ID: 9464336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
    Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
    Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma.
    Hirte HW; Miller D; Tonkin K; Findlay B; Capstick V; Murphy J; Buckman R; Carmichael J; Levine M; Hill W
    Gynecol Oncol; 1997 Jan; 64(1):80-7. PubMed ID: 8995552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients.
    Valle M; Van der Speeten K; Garofalo A
    J Surg Oncol; 2009 Sep; 100(4):331-4. PubMed ID: 19697441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
    Feun LG; Blessing JA; Major FJ; DiSaia PJ; Alvarez RD; Berek JS
    Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.